LSPN Awards 2026 finalists revealed
2 March 2026   Law firms, companies and individuals have been shortlisted across a range of categories, which this year include new awards for excellence in PTAB, trade secrets and medical device work.

Latest Features

Americas
From public use and foreign sales to the challenges of proving infringement, plant patents present unique legal opportunities—and pitfalls—for the agricultural industry, explain Bree Vculek, Gaby Longsworth, and Robert Millonig of Sterne Kessler.
Europe
Traceability and transparency of training practices, and the value of bespoke tool, are among the key AI trends that will be shaped by legal and regulatory developments in 2026, write experts from Rouse.
Europe
A number of ongoing legislative processes are likely to significantly impact the life sciences industry this year, writes Jackie Mulryne of Morgan Lewis.
Europe
The High Court’s ruling clarifies aspects of the SPC waiver but leaves unresolved questions relating to export-country rights and confidentiality, say Claire Phipps-Jones and Luke Norton of Bristows.
Americas
Companies that integrate data rights into their IP strategy with a holistic approach will lead in innovation while minimising risk, says Terri Shieh-Newton of Mintz.
Americas
In the complex world of bsAb patenting, counsel need to turn chefs to serve up success. Benjamin Pelletier of Haynes Boone puts together a menu of dos and don’ts.
Europe
With EU trilogues deadlocked over the package, the future of drug exclusivities and access-linked obligations hangs in the balance. Jackie Mulryne and Paul Ranson of Morgan Lewis pinpoint the flashpoints to watch as negotiators push for a year-end deal.
Big Pharma
Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.
All features


Latest Conference Videos

Americas
Speakers from Greenberg Traurig, Verdiva Bio, Halozyme, and Metsera discuss the implications of the USPTO’s 2024 §112 guidelines on life sciences patents.
Europe
Amanda Simons, J A Kemp, explains how clinical research affects patentability in Europe and how clinical data can be used to strengthen protection.
Biotechnology
Dirk Buehler, Maiwald, discusses how the “try and see” standard is applied before the EPO and its relevance in pharma and biotech cases.
Europe
High-value IP disputes are reshaping life sciences litigation, with perspectives from McDermott Will & Emery, Curevac, Regeneron, HGF, and the UPC.
All videos


More News

20 February 2026   The German biotech claims the newly approved vaccine infringes its mRNA patent, deepening an already complex feud with billions of dollars at stake.
20 February 2026   The new hire has “deep experience in high-stakes International Trade Commission proceedings”, whose specialisms include medical devices, pharma and genomics.
19 February 2026   An EPO appeals board has denied Boston Scientific’s bid to revoke St Jude Medical’s transcatheter aortic valve replacement (TAVR) patent, but declined to hand a complete victory to the patent owner.
19 February 2026   The genetic testing firm claims that a former oncology specialist stole hundreds of confidential files in the dead of night, days before moving to a competitor.
18 February 2026   A lawyer with three decades of experience across energy, technology, life sciences, sports and media has joined the firm's Global Regulatory & IP practice in Milan.
18 February 2026   The science and technology conglomerate’s big diagnostics bet comes with monitoring technology, an AI-powered product pipeline, and a litigation history that has kept Silicon Valley’s biggest player on the back foot.
17 February 2026   With a UK defeat still fresh, the Swedish-British drugmaker has secured breathing room in Australia—but a validity battle and key question of patent law looms at trial.
More news